Form 8-K - Current report:
SEC Accession No. 0001193125-21-209865
Filing Date
2021-07-07
Accepted
2021-07-07 16:01:55
Documents
16
Period of Report
2021-07-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d187752d8k.htm   iXBRL 8-K 31166
2 EX-1.1 d187752dex11.htm EX-1.1 17602
3 EX-5.1 d187752dex51.htm EX-5.1 9814
7 GRAPHIC g187752g16c31.jpg GRAPHIC 2195
8 GRAPHIC g187752g77q28.jpg GRAPHIC 9122
  Complete submission text file 0001193125-21-209865.txt   208646

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA beam-20210707.xsd EX-101.SCH 2885
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE beam-20210707_lab.xml EX-101.LAB 18122
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE beam-20210707_pre.xml EX-101.PRE 11400
9 EXTRACTED XBRL INSTANCE DOCUMENT d187752d8k_htm.xml XML 3348
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39208 | Film No.: 211077443
SIC: 2836 Biological Products, (No Diagnostic Substances)